251 related articles for article (PubMed ID: 21348559)
1. Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
Lynch PM; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
Am J Manag Care; 2010; 16(12):892-6. PubMed ID: 21348559
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis on continuous subcutaneous insulin infusion and multi-point daily insulin injections in the treatment program of type 2 diabetes].
Shu J; Zeng LY; Mu PW; Wang MM; Zhang GC; Chen YM
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jul; 30(7):737-9. PubMed ID: 19957604
[TBL] [Abstract][Full Text] [Related]
3. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
Eby EL; Boye KS; Lage MJ
J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.
Monami M; Lamanna C; Marchionni N; Mannucci E
Exp Clin Endocrinol Diabetes; 2009 May; 117(5):220-2. PubMed ID: 19301231
[TBL] [Abstract][Full Text] [Related]
5. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
6. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
7. A clinical and health economic review of a prefilled insulin pen.
Niskanen L
Curr Med Res Opin; 2010 Oct; 26(10):2431-9. PubMed ID: 20815660
[TBL] [Abstract][Full Text] [Related]
8. Insulin pump therapy in adults.
Didangelos T; Iliadis F
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S109-13. PubMed ID: 21864741
[TBL] [Abstract][Full Text] [Related]
9. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
10. Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes.
David G; Gill M; Gunnarsson C; Shafiroff J; Edelman S
Am J Manag Care; 2014 Nov; 20(11):e490-7. PubMed ID: 25730348
[TBL] [Abstract][Full Text] [Related]
11. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
12. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use.
Perfetti R
Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S79-85. PubMed ID: 20515312
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
St Charles M; Lynch P; Graham C; Minshall ME
Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
[TBL] [Abstract][Full Text] [Related]
14. Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous glucose monitoring system.
Mozdzan M; Ruxer J; Loba J; Siejka A; Markuszewski L
Adv Med Sci; 2006; 51():133-6. PubMed ID: 17357293
[TBL] [Abstract][Full Text] [Related]
15. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe.
Lee LJ; Li Q; Reynolds MW; Pawaskar MD; Corrigan SM
J Med Econ; 2011; 14(1):75-86. PubMed ID: 21231863
[TBL] [Abstract][Full Text] [Related]
16. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
Asche CV; Shane-McWhorter L; Raparla S
Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
[TBL] [Abstract][Full Text] [Related]
17. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
[No Abstract] [Full Text] [Related]
18. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
19. [Intensive insulin therapy].
Landgraf R; Huber RM; Bachmann A; Lohr R
Dtsch Med Wochenschr; 2008 Apr; 133(17):901-12. PubMed ID: 18415916
[No Abstract] [Full Text] [Related]
20. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
